Pro-gastrin-releasing peptide as a marker for the Ewing sarcoma family of tumors
- 59 Downloads
Pro-gastrin-releasing peptide (ProGRP) is an established tumor marker of small cell lung cancer. The purpose of this study was to determine if ProGRP could serve as a tumor marker for the Ewing sarcoma family of tumors (ESFTs).
Sixteen patients with ESFTs (mean age 32 years) were included in this study. As a control group, 42 patients with other tumor types that clinically or pathologically mimic ESFTs were also analyzed. Pre-treatment serum ProGRP and neuron-specific enolase (NSE) levels, the relationships between these levels, and tumor volume were investigated. In addition, serial changes in the serum or plasma ProGRP (6 patients) and NSE levels (5 patients) were measured over the course of treatment.
Pre-treatment serum ProGRP levels were higher than the normal range in 8 of 16 patients; for these eight patients, ProGRP levels positively correlated with tumor volume (R = 0.99). In the control group, ProGRP levels were within the normal range, except for the two patients. Changes in ProGRP levels during treatment were consistent with tumor volume. Serum NSE levels were elevated in 14 of 16 patients with ESFTs and 8 of 42 patients with other tumor types. The range of NSE elevation was much smaller compared to that of ProGRP. Our data indicate that ProGRP is superior to NSE in terms of specificity.
Serum ProGRP levels were elevated in half of the patients with ESFTs and reflected therapeutic response. ProGRP is a reliable tumor marker for the diagnosis of ESFTs and evaluation of treatment response.
KeywordsPro-gastrin-releasing peptide Ewing sarcoma family of tumors Neuron-specific enolase
The authors thank the staffs of the Biobank of the Shizuoka Cancer Center Hospital for sample preparation.
Compliance with ethical standards
Conflict of interest
Dr. Ken Yamaguchi is the inventor of the ProGRP assay system, and he holds patents on this method. He receives honoraria for patent royalties from the Advanced Life Science Institute, Inc. (Saitama, Japan), a company distributing reagents to several in vitro diagnostics companies, for constructing the assay system. None of other authors have any conflict of interest to declare.
- 6.Jaffe R, Santamaria M, Yunis EJ et al (1984) The neuroectodermal tumor of bone. AmJ SurgPathol 8(12):885–898Google Scholar
- 7.Patterson FR, Basra SK (2007) Ewing’s sarcoma. In: Schwartz HS (ed) Orthopaedic knowledge update: musculoskeletal tumors 2. American Academy of Orthopaedic Surgeons, Rosemont, pp 175–183Google Scholar
- 16.Ambros IM, Ambros PF, Strehl S et al (1991) MIC2 is a specific marker for Ewing’s sarcoma and peripheral primitive neuroectodermal tumors Evidence for a common histogenesis of Ewing’s sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 67(7):1886–1893CrossRefGoogle Scholar
- 25.Unni KK, Inwards CY (2010) Ewing tumor. Dahlin's bone tumors, 6th edn. Lippincott Williams and Wilkins, Philadelphia, pp 211–224Google Scholar